This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - 1200.32/34

Afatinib dose adjustment: Effect on safety, efficacy and patient-reported outcomes in the LUX-Lung 3/6 trials in EGFRm+ NSCLC

 

Vera Hirsh, Eng-Huat Tan, Yi-Long Wu, Lecia V. Sequist, Caicun Zhou, Martin Schuler, Sarayut L. Geater, Tony Mok, Cheng-Ping Hu, Nobuyuki Yamamoto, Jifeng Feng, Kenneth O’Byrne, Shun Lu, Yunchao Huang, Martin Sebastian, Isamu Okamoto, Nicolas Dickgreber, Riyaz Shah, Michael Palmer, Angela Märten, Dan Massey, Carl Samuelsen, James Chih-Hsin Yang

Related Material

Learn more about the science behind this poster in the videos, papers and other materials below.

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Yang JC-H, et al. Ann Oncol. 2016;27:2103-10.

LUX-Lung 3 Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations

Sequist LV, et al. J Clin Oncol. 2013;31:3327–34

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Wu Y-L, et al. Lancet Oncol. 2014;15:213–22.

Related information

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

WCLC 2017

Find information on afatinib and nintedanib's clinical data and Boehringer Ingelheim's activities at WCLC 2017
Back to top